SCHEMBL1098518

SCHEMBL1098518

O=S(=O)(c1cccnc1)N(CCCC(F)(F)F)c1cc2ccccc2s1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.41
PTGER2 P43116 7/20 0.41
MAPT P10636 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
NR1D1 P20393 1/20 0.33
NR1H3 Q13133 1/20 0.33
KEAP1 Q14145 2/20 0.33
NFE2L2 Q16236 2/20 0.33
TBXAS1 P24557 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
KMT2A Q03164 1/20 0.32
SLC40A1 Q9NP59 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098832 0.86 PTGER2 (0.43) PTGER2MAPTTRPM8KEAP1NFE2L2
SCHEMBL1100530 0.80 RORC (0.45) RORCMAPTNR1H3
SCHEMBL1107246 0.80 RORC (0.40) RORCKEAP1NFE2L2ESR1ESR2
SCHEMBL1100059 0.80 ALOX5 (0.43) TRPM8
SCHEMBL12000790 0.79 ALDH1A1 (0.41) RORCTRPM8KEAP1NFE2L2ESR1
SCHEMBL1098250 0.79 ESR1 (0.39) RORCMAPTTRPM8KEAP1NFE2L2
SCHEMBL1099598 0.79 RORC (0.41) RORCPTGER2MAPTTRPM8KEAP1
SCHEMBL1098086 0.78 RORC (0.42) RORCPTGER2MAPTTRPM8KEAP1
SCHEMBL1098095 0.77 ESR1 (0.34) RORCTRPM8ESR1ESR2
SCHEMBL1097657 0.77 PTGER2 (0.43) RORCPTGER2TRPM8NR1D1NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885PTGER2 297/4885MAPT 3324/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885PTGER2 297/4885MAPT 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.